Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

PURPOSE: This phase III randomized open-label clinical trial was designed to evaluate the efficacy and safety of the steroidal aromatase inactivator exemestane versus the antiestrogen tamoxifen as first-line treatment for metastatic breast cancer (MBC) in postmenopausal women. PATIENTS AND METHODS:...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Paridaens, Robert J., Dirix, Luc Y., Beex, Louk V., Nooij, Marianne, Cameron, David A., Cufer, Tanja, Piccart, Martine J., Bogaerts, Jan, Therasse, Patrick
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2008
Gaiak:
Breast Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2652082/
https://ncbi.nlm.nih.gov/pubmed/18794551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.14.4659
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak